The Analytical Scientist

April 2018

Spokesperson: Andrew James, Ellutia

In many regions, cannabis is now considered by the public as a medicine. However, compared to pharmaceutical industry standards, it is easy to see where it falls short in terms of rigorous safety and potency testing. Andrew James, Marketing Director at Ellutia, discusses the need for more in-house testing throughout the supply chain. Read the article here.